P reeclampsia is a multisystemic disorder characterized by new-onset hypertension usually occurring in the third trimester of pregnancy.
P reeclampsia is a multisystemic disorder characterized by new-onset hypertension usually occurring in the third trimester of pregnancy. 1 Preeclampsia effects ≈ 5% to 10% of all births in the United States each year and is the leading cause of preterm births, morbidity, and mortality for both the mother and fetus during pregnancy. [1] [2] [3] [4] The origins of preeclampsia are unknown; however, it is widely believed that the placenta is the culprit of the disease. During preeclampsia, several factors are released that play a role in the disease, such as sFlt-1 (soluble fms-like tyrosine kinase-1), inflammatory cytokines, oxidative stress molecules, cytolytic natural killer (NK) cells, and the AT1-AA (agonistic Ang II [angiotensin II] type 1 receptor autoantibody). [1] [2] [3] [5] [6] [7] As of today, there is no cure for preeclampsia except for the delivery of the fetal placenta unit. To better understand the cause, pathology, and efficacy of possible treatments for preeclampsia, we use the reduced uterine perfusion pressure (RUPP) rat model. 8 Similar to women with preeclampsia, RUPP rats have increased sFlt-1, inflammatory cytokines, cytolytic NK cells, reactive oxygen species, and AT1-AAs. 3, 8, 9 AT1-AAs bind with high affinity to a 7 amino acid sequence on the second extracellular loop causing activation of the AT1 (Ang II type 1) receptor. 6, 7, [10] [11] [12] [13] [14] [15] AT1-AA binding of the receptor has been shown to increase intracellular calcium levels and stimulate activation of intracellular mean arterial pressure (MAP)/ERK kinase and TNF (tumor necrosis factor)-α pathways similar to Ang II. 6, 7, [10] [11] [12] [13] [14] [15] Both human and animal AT1-AAs isolated from preeclampsia patients or RUPP rats reproduce the preeclampsia-like phenotype when given to pregnant rodents. These models of AT1-AA-induced hypertension during pregnancy have reduced glomerular filtration rate (GFR), increased blood pressure, oxidative stress, renal artery resistant index, reduced pup weight, and several circulating factors associated with preeclampsia, such as sFlt-1, sEng, inflammatory cytokines, ET (endothelin)-1 , and endothelial microparticles. 10, [16] [17] [18] [19] [20] [21] [22] [23] [24] Landmark studies by the Xia laboratory demonstrated that AT1-AA titer in preeclampsia women is proportional to sFlt-1 and the severity of preeclampsia. 25 Furthermore, studies by Walther et al 26 show that AT1-AAs are detected within the 2nd trimester of a human pregnancy is associated with abnormal uterine perfusion pregnancies, suggesting that AT1-AA's appear early in the diagnosis of preeclampsia and may play a critical role in the pathogenesis of preeclampsia and intrauterine growth restriction. Additional studies by the Xia laboratory showed that hypertension and elevated sFlt-1 l in pregnant mice, mediated by AT1-AAs from preeclampsia women, was blunted by ARB (AT1 receptor blocker) treatment, suggesting that the increase in sFlt-1 is downstream of AT1 receptor activation. 27 Our previous studies have shown that AT1-AAinduced hypertension in pregnant rats occurs with increased ET-1, sFlt-1, and oxidative stress. 10, 16, 18, 20 Administration of an ET-A receptor antagonist or an ARB reduced blood pressure and these stimulated factors supporting the idea that AT1-AAs cause hypertension during pregnancy through AT1R mediated ET-1, oxidative stress, and sFlt-1 upregulation. 16, 18, 20, 28 However, we cannot use losartan during pregnancy because of fetal toxicity, therefore, the utilization of an inhibitory peptide to prevent the AT1-AA from activating the AT1 receptor could not only attenuate the increase in vasoactive factors and oxidative stress but also prevent the rise in maternal blood pressure and thereby could be advantageous to improve outcomes in response to placental ischemia during pregnancy.
Therapies targeted specifically against the AT1-AA to keep it from binding to the 2nd extracellular loop of the AT1 receptor have previously been performed by the laboratory of Yang Xia. Xia laboratory administered a linear 7 amino acid sequence peptide corresponding to the binding site on the AT1 receptor to pregnant mice receiving the human AT1-AA. These studies showed that the peptide was able to improve trophoblast invasion, calcium mobilization, intrauterine growth restriction, proteinuria, renal pathology, and hypertension. 14, 16, 29, 30 In vitro studies from our laboratory show that a similar linear 7 amino acid sequence significantly improves renal afferent arteriolar vasoconstriction. 16 However, none of these studies address the role of the naturally occurring AT1-AA produced in response to placental ischemia. In this study, we examined the effects of a newly constructed, modified AT1-AA inhibitory peptide, chronically administered to RUPP rat model of preeclampsia during pregnancy. It is important to note that this modified peptide is different from the linear peptide used in previous publications. 14, 16, 29, 30 This newly modified peptide contains the 7 AA sequence along with protein capping of the N and C terminus of the peptide. Protein capping is a process commonly used to increase peptide half-life and to protect exogenous peptides from protein lysis and degradation when used in the whole animal. Based on previous studies, we hypothesized that this modified peptide would bind to circulating AT1-AAs, to inhibit AT1-AAs from binding to the AT1 receptor thereby decreasing sFlt-1, ET-1, and reactive oxygen species; thus improving blood pressure and renal and vascular function in RUPP rats.
Methods
The techniques and data that support the findings of this study are available from the corresponding author on reasonable request.
All animal protocols were approved by the Institutional Animal Care and Use Committee at the University of Mississippi Medical Center. Pregnant Sprague Dawley rats purchased from Envigo (Indianapolis, IN) were used in this study. Rats were housed in a temperature-controlled room (75°F) with a 12-hour light and dark cycle each day and maintained on a normal diet with free access to food and water. All experiments performed were in accordance with the National Institutes of Health guidelines for use and care of animals.
Measurement of MAP and Renal Function in RUPP Rats
Pregnant SD rats were randomly dived into 4 groups: normal pregnant (NP) rats (n=23), NP+AT1-AA inhibitory peptide (‵n7AAc′; n=3), RUPP rats (n=32), and RUPP+‵n7AAc′ (n=24). On day 14 of pregnancy, the RUPP surgery was performed, with 1 group of RUPP rats receiving a miniosmotic pump. RUPP surgery consisted of placing constrictive silver clips on the aorta (0.203 mm clips) superior to the iliac bifurcation and on the ovarian vessels (0.100 mm clips). The minipump implanted IP delivered the modified capped AT1-AA inhibitory peptide (‵n7AAc′; Thermo Fisher Scientific, Waltham, MA) at a dose of 144 μg/day through day 19 of gestation. The modified AT1-AA inhibitory peptide is different from the linear peptide sequence, used in previous studies 6, 16, 18, 22, 25, 27, 29 by a process referred to as protein capping (Thermo Fisher Scientific, Waltham, MA). The advantages of capping the peptide is for stabilization of the peptide in vivo, protection against peptidases, and to more accurately mimic natural peptides in the circulation. Minipumps were also inserted into NP rats on day 14 of pregnancy. This dose was based on previous studies performed in our laboratory. 16, 23, 31 Note that we only measured the blood pressure, pup weight, litter size, and placental size for NP+‵n7AAc′ rats. We did not perform further analysis on these rats because the blood pressure and maternal outcomes of these rats were similar to NP values and did not seem to alter the physiological state of a normal pregnancy in rats. Furthermore, the AT1-AA is not detectable in NP rats thus further molecular analysis was not performed. 18 On day 18 of gestation, using isoflurane anesthesia, catheters were inserted into the carotid artery and jugular vein to measure the blood pressure and infusion of fluorescein isothiocyanate (FITC)-sinistrin to determine GFR. On day 19 of gestation, GFR and conscious blood pressure (MAP) were determined. On day 19, rats were anesthetized and all of the hair on the upper back below the ears were shaved and removed to reduce interference or autofluorescence of sinistrin. For determination of GFR, a miniaturized device (NIC-Kidney, Mannheim Pharma & Diagnostics, Mannheim, Germany) composed of 2-light-emitting diodes that can transcutaneously excite and measure the clearance of FITC-sinistrin was used and baseline fluorescence was collected for 10 to 15 minutes, followed by a bolus injection of FITC-sinistrin (3 mg/100 g body weight in 0.2 mL of 0.9% irrigation saline). Continuous fluorescence was measured for 2 hours and clearance curves analyzed using the MPD Lab Ver 1.0RC3 software. The half-life (t 1/2 ) for the clearance of FITC-sinistrin is determined 45 minutes postinjection using a 1-compartment model. The t 1/2 value is converted to GFR (mL/min per 100 g body weight) using the following semiempirical equation developed and validated by the manufacturer: GFR=31.26 [mL/100 g body weight]/t 1/2 [min].
32 MAP was measured after placing the rats in individual restraining cages. 23, 31 Briefly, arterial pressure was monitored with a pressure transducer (Cobe III transducer CDX Sema) and recorded continuously for 45 minutes after a 30-minute stabilization period. Subsequently, blood and urine samples were collected. Pup weights were obtained and placentas and kidneys were harvested, weighed, and stored in −80°C for further use. 23, 31 Plasma creatinine was measured using the LabAsay Creatinine kit (Jaffe method; Wako Pure Chemical Industries, Ltd, Osaka, Japan) according to the manufacturer's instructions. Standards ranged from 10 to 1.25 mg/dL. This colorimetric assay determined the amount of plasma creatinine, which was expressed as mg/dL.
Effect of ‵n7AAc′ on Uterine Artery Resistance Index in RUPP Rats
Uterine artery resistance indexes (UARIs) measurements were obtained on gestational day 18 via Doppler sonography, using the Vevo 770 unit (Visual Sonics) with a 30-Hz transducer (model number 710B) as described previously. 28, 33 Briefly, 2 to 4 images and measurements of Doppler velocimetry were taken on both the left and right uterine arteries. The peak systolic velocity (PSV) and end-diastolic flow velocity (EDV) measurements were taken from the Doppler images and used to calculate UARI, using this equation UARI=(PSV−EDV)/PSV.
33

Effect of ‵n7AAc′ on Placental PPET-1 Expression in RUPP Rats
Placental total RNA was extracted using the RNeasy Protect Mini kit (Qiagen, Hilden, Germany). Real-time PCR was used to determine levels of placental PPET-1 (preproendothelin-1). cDNA was synthesized from 1 μg of RNA with Bio-Rad Iscript cDNA reverse transcriptase, and real-time PCR was performed using the Bio-Rad Sybre Green Supermix (Bio-Rad, Hercules, CA). Placental PPE expression is measured as the fold difference from RUPP versus NP and RUPP+‵n7AAc′ versus NP. 16, 33 Effect of ‵n7AAc′ on Circulating Factors: Nitrate and Nitrite, Isoprostanes, and sFlt-1 Plasma nitrate and nitrite was measured using the Nitrate/Nitrite Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, MI) according to the manufacturer's instructions and reagents. Plasma isoprostanes levels were measured using the 8-Isoprostane EIA kit (Cayman Chemical, Ann Arbor, MI) according to the manufacturer's instructions. 23 The intra-assay and interassay variation in concentration (coefficient of variation [CV] ) for this kit were determined at multiple points on the standard curve, with CVs<20%. Plasma soluble VEGF (vascular endothelial growth factor) receptor 1 (sFlt-1) content was determined using commercial Quantikine ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. The inter-and intra-assay variability for the concentration was determined by the kit to be 8.4% and 7.2%, respectively.
Effect of Placenta NK Cells Measured by Flow Cytometry
At the time of harvest, kidneys and placentas will be collected. Lymphocytes were isolated from tissues via centrifugation on a cushion of Ficoll-Hypaque (Lymphoprep, Accurate Chemical & Scientific Corp, Westbury, NY). For flow cytometric analysis, 1×10 6 cells were incubated for 30 minutes at 4°C with antibodies against rat Anti-NK Cell Activation Structures (ANK61) or rat Anti-NK Cell antibody (ANK44; AbCam, Cambridge, MA). ANK61 binds to the killer cell activation structure that is expressed on all NK cells, whereas ANK44 is only expressed on stimulated, cytotoxic NK cells. 34 After washing, cells were labeled with secondary FITC (AbCam) antibody for 30 minutes at 4°C. As a negative control for each individual rat, cells were treated exactly as described above except they were incubated with isotype controls antibodies conjugated to FITC alone. Subsequently, cells were washed, fixed, and resuspended in 500 µL of Rosswell Park Memorial Institute medium and analyzed for single staining on a Gallios flow cytometer (Beckman Coulter, Brea, CA). Lymphocytes were gated in the forward and side scatter plot. Cells that stained as ANK61+ will be designated as NK cells. Cells that stain as ANK44+ were designated as activated NK cells. The percent of positive stained cells above the negative control was collected for individual rats and the mean values for each experimental group were taken.
Statistical Analysis
All data are presented as mean±SEM. Data were analyzed by 1-way ANOVA with Bonferroni post hoc analysis or by Student t test comparing each group to each other as needed. All statistical analysis was performed with GraphPad Prism 6 software (GraphPad Software, La Jolla, CA). P<0.05 was considered statistically significant.
Results
Effect of ‵n7AAc′ on MAP, Fetal Growth, UARI, and Renal Function in RUPP Rats
MAP, a major diagnostic factor of preeclampsia, was elevated in RUPP rats (n=32, 123±2 mm Hg) compared with NP rats (n=23, 99±2 mm Hg, P<0.05) and was normalized to NP levels with RUPP+‵n7AAc′ (n=24, 105±3 mm Hg, P<0.05 versus RUPP; Figure 1 ). MAP was similar to NP rats in NP+‵n7AAc′ rats (100±7 mm Hg), suggesting that the inhibitor does not affect the blood pressure in NP rats. These data indicate that inhibiting AT1-AA activation of the AT1R decreases blood pressure in response to placental ischemia suggesting that the AT1-AA is a major contributor to hypertension in the RUPP rats.
Next, we examined markers of fetal growth restriction, such as litter size, pup weight, and placental weight. The litter size was lower in RUPP rats (n=32, 6±0.7) compared with NP rats (n=23, 13±0.4, P<0.05; Figure 2A ) and was unchanged in RUPP+‵n7AAc′ rats (n=24, 6±0.9, ns versus RUPP; Figure 2A ). The average pup was smaller for RUPP (1.98±0.04 g) and RUPP+‵n7AAc′ (2.13±0.05 g) rats in comparison to NP (2.49±0.08 g) rats (P<0.05; Figure 2B ). Placental weight was decreased for RUPPs (0.54±0.02 g) and RUPP+‵n7AAc′ (0.53±0.02 g) rats in comparison to NP (0.69±0.05 g) rats (P<0.05; Figure 2C) . No difference was observed in the litter size, average pup, and placental weight between RUPP and RUPP+‵n7AAc′ rats (Figure 2A through 2C ). In addition, the litter size, pup weight, and placental weight were 15±1, 2.04±0.08 g, and 0.51±0.01 g, respectively for NP+‵n7AAc′ rats which were not different than NP rats. Although AT1-AA inhibition did not prevent fetal growth restriction in RUPP rats, there was no further reduction of fetal growth restriction with AT1-AA inhibition.
The UARI, which is a measurement of uterine artery vascular resistance, was increased in RUPP (n=9) versus NP (n=11) rats (0.71±0.02 versus 0.49±0.02, P<0.05; Figure 3 ). UARI decreased in RUPP+‵n7AAc′ (n=8) versus RUPP rats (0.55±0.03 versus 0.71±0.02, P<0.05) and was similar to NP values (Figure 3 ).
There was a tendency for a decrease in renal function (GFR) for RUPP (n=6, 3.1±0.2 mL/min) versus NP rats (n=9, 3.4±0.2 mL/min, ns; Figure 4A ). GFR was normalized to NP levels in RUPP+‵n7AAc′ (n=8, 3.4±0.3 ns; Figure 4A ). Plasma creatinine was more than doubled in RUPP rats (n=9; 0.86±0.32 mg/dL) compared with NP rats (n=7; 0.30±0.02 mg/dL, P=0.14). The same trend was also observed comparing RUPP to RUPP+‵n7AAc′ rats (n=7; 0.86±0.32 versus 0.38±0.05 mg/dL, P=0.21; Figure 4B ). These data taken together suggest that RUPP decreases renal function, which can be prevented in pregnant rats by AT1-AA inhibition.
Effect of ‵n7AAc′ on Circulating Factors: sFlt-1, Nitrate and Nitrite, Isoprostanes, and Placental ET-1 in RUPP Rats
Plasma sFlt-1, a potent antiangiogenic factor that causes vasoconstriction and is strongly associated with preeclampsia, levels were elevated in RUPP (n=4) versus NP (n=4) rats (176±37 versus 77±15 ρg/mL, P<0.05; Figure 5A ). Importantly, the rise in sFlt-1 was prevented with ‵n7AAc′ as there was no change between NP and RUPP+‵n7AAc′ rats (n=4; 77±15 versus 86±9 ρg/mL, ns; Figure 5A ). Plasma levels of nitrate and nitrite, metabolites of nitric oxide (NO), were decreased in RUPP (n=5) rats compared with NP (n=4) rats (14.01±1.47 versus 19.98±1.02 µmol/L of NO 3 , P<0.05; Figure 5B ). Plasma nitrate and nitrite levels were returned to NP levels in RUPP+‵n7AAc′ (n=8; 18.27±1.56 µmol/L of NO 3 ; Figure 5B ), suggesting that NO bioavailability is maintained in RUPP rats treated with AT1-AA inhibition. There was a 7-fold increase in circulating isoprostane levels, a reactive oxygen species and marker of oxidative stress which can cause vasoconstriction, in RUPP (n=9) rats versus NP (n=4) rats (20 117±6304 versus 2809±1375 pg/mL, P<0.05) and a 4.5-fold increase in RUPP versus RUPP+‵n7AAc′ rats (n=8; 4311±2249 versus 2809±1375 pg/mL, P<0.05; Figure 5C ). No difference in NP and RUPP+‵n7AAc′ rats levels, suggesting that AT1-AA inhibition normalized RUPP isoprostanes to that of NP values ( Figure 5C ). RUPP (n=7) rats displayed a 4-fold increase in placental PPET, precursor for ET-1 a potent vasoconstrictor, message versus NP (n=6) rats (4.2±0.20 versus 1.0±0.33, P<0.05; Figure 5D ). Placental PPET expression was also elevated in RUPP versus RUPP+‵n7AAc′ (n=4) rats (4.2±0.20 versus 2.3±0.39, P<0.05; Figure 5D ). These data suggest that AT1-AA inhibition prevents vasoconstriction and hypertension, by decreasing sFlt-1, oxidative stress, ET-1, and increasing NO bioavailability in RUPP rats.
Effect of ‵n7AAc′ on Placental NK Cells in RUPP Rats
NK cells which are elevated in preeclampsia, were measure by flow cytometry in the placenta. Total placental NK cells in RUPP rats (n=11, 18.6±6.6% gated) are elevated over NP (n=9, 7.5±2.3% gated) and RUPP+‵n7AAc′ (n=6, 6.4±3.2% gated) rats ( Figure 6A ). Placental cytolytic NK cells were significantly increased in RUPP (n=11) rats versus NP (n=9) rats (8.3±1.7% versus 2.1±1.6% gated, P<0.05; Figure 6B ) and were decreased in RUPP+‵n7AAc′ (n=6) rats (8.3±1.7% versus 2.8±0.9% gated, P<0.05, RUPP versus RUPP+‵n7AAc′; Figure 6B ). Thus AT1-AA blockade prevents placental NK cell activation in RUPP rats.
Conclusions
The major finding of this study is that epitope binding of the AT1-AA in placental ischemic rats prevents the Figure 2 . A, The number of pups was decreased for reduced uterine perfusion pressure (RUPP) and RUPP+‵n7AAc′ vs normal pregnant (NP) rats. B, Placental weight was decreased for RUPP and RUPP+‵n7AAc′ vs NP rats. C, Pup weight was decreased for RUPP and RUPP+‵n7AAc′ vs NP rats. Although, there was no difference between RUPP and RUPP+‵n7AAc′ with number of pups, placental weight, and pup weight, there was no further decrease with RUPP+‵n7AAc′. Statistical changes was determined using 1-way ANOVA with Bonferroni post hoc analysis, *P<0.05 vs NP. pathophysiological symptoms associated with preeclampsia in women. Inhibition of AT1-AA binding to the AT1 receptor normalized the increase in blood pressure, in which we think was achieved by suppressing ET-1, plasma sFlt-1, and isoprostanes. It also improved systemic NO bioavailability and reduced cytolytic NK cells. Moreover, renal function was improved, because of reduced oxidative stress, ET-1, sFlt-1, and improved NO bioavailability, which contributed to the improved blood pressure response to placental ischemia. This study supports findings that a major culprit responsible for the cause of preeclampsia are AT1-AAs. Therefore, this study, in conjunction with studies performed by the Xia laboratory, support the idea that inhibiting the AT1-AA from activating the AT1R could be a potential therapeutic option for preeclampsia.
AT1-AAs were first discovered in women with preeclampsia by Wallukat et al 6 in 1999, when they isolated immunoglobulins from the serum of preeclamptic women. They showed that these antibodies had the same affinity and ability to activate the AT1 receptor as Ang II. In these initial studies, AT1-AA activation of the AT1 receptor on cultured neonatal rat cardiomyocytes was inhibited with the addition of clinically used ARBs to the media. 6 However, the use of ARBs and other clinical pharmaceuticals used to inhibit the endogenous renin-angiotensin-aldosterone system during pregnancy are deleterious to the fetus. Therefore, new modalities to block the actions of endogenously produced AT1-AA without interfering with the renin-angiotensin-aldosterone system could improve the clinical management of preeclampsia.
An important new finding in this study is the decrease in placental NK cells. We have recently shown that RUPP rats have increased cytolytic NK cells which are mediators of oxidative stress and secrete inflammatory cytokines. 9 In the case of autoimmunity, cytolytic NK cells are targeted toward normal tissues thereby causing inflammation and tissue damage. 35 Therefore, we hypothesize that the increase in cytolytic NK cells in RUPP rats contributes to the pathology of preeclampsia. In fact, we recently depleted placental NK cells in RUPP rats and found that this significantly improved blood pressure and inflammation, Figure 4 . A, Glomerular filtration rate (GFR) had a tendency to decrease with reduced uterine perfusion pressure (RUPP) vs normal pregnant (NP) rats. B, Plasma creatinine was increased with RUPP vs NP rats. Both were normalized in RUPP+‵n7AAc′ to that of NP levels. Figure 5 . A, Plasma sFlt-1 (soluble fms-like tyrosine kinase-1) is increased in reduced uterine perfusion pressure (RUPP) vs normal pregnant (NP) rats and returned to NP levels in RUPP+‵n7AAc′ rats. B, Plasma nitrate and nitrite (metabolites of NO) was decreased in RUPP vs NP rats and restored to NP levels in RUPP+‵n7AAc′ rats. C, Plasma circulating isoprostanes showed a 7-fold increase in RUPP vs NP rats. Isoprostanes significantly and greatly decreased in RUPP+‵n7AAc′ vs RUPP rats to NP levels. D, Placental PPET (preproendothelin; precursor to endothelin 1) message expression was increased 4-fold in RUPPs vs NP rats. Placental PPET expression was decreased but not to NP levels, in RUPP+‵n7AAc′ vs RUPP rats. Statistical changes was determined using 1-way ANOVA with Bonferroni post hoc analysis, *P<0.05 vs NP and +P<0.05 vs RUPP.
however, this technique may not be possible for treatment of the pregnant mom. 9 Thus the utilization of the method presented in this study to block AT1-AA lead to a reduction in cytolytic NK cells, could be efficacious to the treatment of preeclampsia.
In addition to studying NK cells, we previously examined the effects of an agent used clinically to suppress B lymphocytes known as rituximab. Administration of rituximab to RUPP rats depleted B cell and also reduced the AT1-AA in RUPP rats. 36 Although administration of rituximab depleted B cells, significantly reduced AT1-AA and blood pressure in RUPP rats, the effects of B cell depletion could have detrimental effects in the fetus. In fact in the drug information pamphlet accompanying rituximab warns that B cell depleting agents cross the placental barrier and are present in the newborns of treated women and macaques while pregnant. Given the rapid maturation of the immune system that occurs in newborns B cell depletion could have serious long-term negative effects on children. Therefore other therapeutic strategies are needed to combat the detrimental effects caused by the AT1-AA during pregnancy, whereas leaving B cell function intact. Thus although standard techniques of immune suppression could be advantageous to use during preeclampsia, designing a new therapeutic which allows for normal B cell function, normal NK cell function without interrupting the renin-angiotensin-aldosterone system would greatly advance the treatment of this disease.
In vivo studies in our laboratory and others have shown that AT1-AA infusion into rats increases the blood pressure, oxidative stress, the vasoconstrictor ET-1, and other circulating factors associated with preeclampsia, such as sFlt-1, sEng, and endothelial microparticles. 8, 10, 16, 18, 20 ET-1 and sFlt-1 increase vasoconstriction of blood vessels and decrease vasodilators, such as NO. In this study, we demonstrate that the AT1-AA inhibiting peptide improved endothelial function as demonstrated by reduced UARI, ET-1, sFlt-1, and improved NO. Reduced NO is a marker of endothelial dysfunction which contributes to hypertension. Plasma nitrate and nitrite, metabolites of NO, were decreased in RUPP rats and returned to NP levels in RUPP rats treated ‵n7AAc′. There was a striking 7-fold increase in circulating isoprostanes in RUPP rats that returned to NP levels after AT1-AA inhibition. These data suggest the overall importance of AT1-AA blockade to restore circulating factors to a more NP milieu, thus indicating 1 pathway to improve maternal symptoms and thus allow preeclampsia pregnancies to continue, which could then improve fetal outcomes as well.
In RUPP+‵n7AAc′ there was a significant decrease in circulating sFlt-1. sFlt-1 is a splice variant of the VEGF receptor Flt1 lacking the transmembrane and cytoplasmic domains. This molecule is produced by the placenta and functions as a VEGF antagonist. [37] [38] [39] VEGF is important for angiogenesis, which is the formation of new vessels and is needed during trophoblast invasion for placental formation and endothelial cell function. 38 Under physiological conditions, VEGF functions through the NO pathway and helps to maintain vascular tone and normalize blood pressure. Early studies by Maynard et al, 38 showed that both plasma levels and placental mRNA expression of sFlt-1 was elevated in preeclamptic patients versus NP patients. Furthermore, the same study showed that severity of preeclampsia was correlated with sFlt-1 levels. Xia et al, 30 also verified that severity of preeclampsia was correlated with sFlt-1 along with a strong correlation between sFlt-1 and AT1-AAs. Our data from this study confirms the important role that AT1-AAs play to stimulate sFlt-1 and suggests that a reduction in sFlt-1 via ‵n7AAc′ may serve as a mechanism to improve NO production, oxidative stress, endothelial function, and thus hypertension in RUPP rats.
One mechanism important for either AT1-AA or sFlt-1-induced hypertension is the upregulation of ET-1. [37] [38] [39] [40] ET-1 is a potent vasoconstrictor made primarily by endothelial cells. 41 ET-1 regulates salt and water homeostasis via it effects on the renin-angiotensin-aldosterone system and vascular tone. 41 ET-1 opposes the actions of potent vasodilators, such as NO, prostacyclin, prostaglandins, and natriuretic peptides. 41 The overall actions of ET-1 is to increase vascular tone and cause hypertension. ET-1 elevation is prevalent and part of the pathology of many disease including preeclampsia via its activation of the ET-1 A receptor. 16, 41, 42 ET-1 is derived from its initial product PPET, which is cleaved into proendothelin-1, then cleaved to big ET, and last cleaved to its biological active form of ET. 41 Several experimental studies with animal models of preeclampsia, including the RUPP model, have elevated renal, placental, and vascular mRNA expression of PPET. 4, 42 Importantly, we have shown that AT1-AA-induced hypertension is associated with increased production of PPET-1 in the kidney, vasculature, and placenta. AT1-AA-induced hypertension can be blocked with an ET-1 A receptor antagonist; however, this is not recommended for controlling blood pressure during pregnancy. This data highlights the importance of inhibiting endogenous AT1-AA-mediated stimulation of ET-1 as yet another mechanism to reduce blood pressure in response to placental ischemia. The decrease in UARI with AT1-AA inhibition treated RUPP rats, suggest a decrease in placental vasoconstriction and placental ischemia in these rats, despite the RUPP surgery. This decrease may be because of the increase NO bioavailability and decrease in vasoactive agents, such as reactive oxygen species, ET-1, and sFlt-1. We think that the inhibition of AT1-AA from binding to the AT1 receptor will directly and indirectly decreases vasoconstriction. Directly, AT1-AAs are known to increase vascular tone when placed on renal afferent arterioles and to increase renal vascular resistance when administered in vivo. 16, 23 Furthermore, blockade of the AT1 receptor activation, via administration of an Ang II converting enzyme inhibitor and Ang II receptor blocker, blunted the increase in AT1-AA vasoconstriction and increased vascular resistance. 16 Indirectly, the decrease in vascular resistance in the uterine arterioles may be facilitated by the mechanisms mentioned above. We have shown in earlier studies that tempol (an antioxidant) treated rats with AT1-AA infusion improved both blood pressure and the renal artery resistance index, whereas the ET-1 receptor blocker improved the blood pressure and the UARI in RUPP rats. 4, 28 Thus suggesting that reducing oxidative stress and ET-1 are mechanism of improved renal and uterine endothelial function.
Although there were no changes or improvements with pup weight, placental weight, or litter size in RUPP rats treated with AT1-AA inhibition, it is important to note that we did not see a further decrease in pup weight, placental weight, or litter size with treatment. This suggest that the AT1-AA inhibition is not toxic to the pups. Moreover, it is important to remember that the invasive RUPP procedure, is induced by manually placing surgical clips on blood vessels to reduce flow and nutrients to the growing fetus. Thus it is possible that without mechanical restraint of blood vessels, AT1-AA inhibition might be able to improve fetal outcomes in addition to those observed in the mother.
Perspectives
In summary, AT1-AA inhibition prevents maternal blood pressure, secretion of antiangiogenic and vasoconstrictive factors, renal function, systemic NO bioavailability, and oxidative stress in response to placental ischemia. Improvement in these factors contributed to improved blood pressure and renal function in the moms. Moreover, we hypothesize that AT1-AA inhibition during pregnancy could lead to short-term improvements for mom and the baby during pregnancy which could result in long-term improvements for both individual's health risks of developing cardiovascular-renal disease and stroke later in life. Because of complications caused by angiotensinconverting enzyme inhibitors, ARBs, or B cell depletion during pregnancy, specific AT1-AA inhibition may be an option to consider for better management of preeclampsia.
